BIOCON PHARMA LIMITED

Anthem Biosciences is launching a ₹3,395 crore IPO next week, positioning itself as a key alternative to Chinese CRDMOs as global pharma companies diversify supply chains amid geopolitical uncertainties.

Biocon Ltd. is seeking regulatory approval for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting Canada as its first major market entry by 2026.

Regeneron filed a new patent infringement complaint against Amgen on June 17, 2025, asserting U.S. Patent No. 12,331,099 covering a stable liquid ophthalmic formulation without buffer requirements.

Biocon has received regulatory approval from India's Central Drugs Standard Control Organisation (CDSCO) for its diabetes drug liraglutide, marking a significant milestone for the company's pharmaceutical portfolio.

Biocon Limited has received approval from India's CDSCO for its generic version of Victoza (liraglutide), marking the company's first vertically integrated GLP-1 diabetes therapy clearance in the country.

Biocon chairperson Kiran Mazumdar-Shaw announced plans for a ₹4,500 crore qualified institutional placement to convert structured venture debt into equity, aiming to strengthen the company's balance sheet.

• Biocon plans to invest $150 million in capital expenditure over the next two years, with $100 million allocated to biologics expansion in Malaysia and $50 million to generics. • The biopharmaceutical company reported a 153% surge in Q4 net profit to Rs 344 crore, driven by strong growth in generics and steady progress in biosimilars. • Biocon is expanding its product portfolio with recent launches of lenalidomide and dasatinib in the US, liraglutide in the UK, and plans to launch bevacizumab and insulin aspart in the US market.

• Biocon Group reported strong Q4FY25 performance with revenue reaching Rs 4,454 crore, up 15% year-on-year, driven by significant market share gains in biosimilars and new product launches. • The company launched Yesintek™ (ustekinumab-kfce), its fifth biosimilar in the U.S. market, which is witnessing strong physician adoption and broad formulary coverage with potential to benefit 100 million lives. • Four of Biocon's biosimilars have each recorded sales of USD 200 million in FY25, with the company's biosimilars business growing 15% for the full year and serving over 5.8 million patients globally.

Biocon launched a ₹4,500 crore Qualified Institutional Placement with a floor price of ₹340.20 per share to strengthen its financial position.

Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, has received FDA approval for Norepinephrine Bitartrate Injection USP, used to raise blood pressure in adults with acute hypotension.